Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SULT1A1 | P50225 | 1/20 | 0.84 |
| ▸ | APP | P05067 | 10/20 | 0.74 |
| ▸ | GLA | P06280 | 1/20 | 0.71 |
| ▸ | GAA | P10253 | 1/20 | 0.71 |
| ▸ | TP53 | P04637 | 1/20 | 0.62 |
| ▸ | MAPT | P10636 | 1/20 | 0.62 |
| ▸ | THRB | P10828 | 1/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.62 |
| ▸ | SNCA | P37840 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1984039 | 0.92 | SULT1A1 (0.72) | SULT1A1APPGLAGAATP53 | |
| SCHEMBL1984042 | 0.92 | SULT1A1 (0.72) | SULT1A1APPGLAGAATP53 | |
| SCHEMBL5429982 | 0.91 | APP (0.83) | SULT1A1APPGLAGAASMN1; SMN2 | |
| SCHEMBL26017584 | 0.87 | APP (0.76) | SULT1A1APPGLAGAASNCA | |
| SCHEMBL23766560 | 0.85 | APP (0.74) | SULT1A1APPGLAGAAMAPT | |
| SCHEMBL13806279 | 0.85 | APP (1.00) | SULT1A1APPGLAGAA | |
| SCHEMBL1572680 | 0.85 | APP (1.00) | SULT1A1APPGLAGAA | |
| SCHEMBL21752042 | 0.85 | APP (0.74) | SULT1A1APPGLAGAASMN1; SMN2 | |
| SCHEMBL1572797 | 0.85 | APP (0.74) | SULT1A1APPGLAGAASMN1; SMN2 | |
| SCHEMBL12974045 | 0.85 | APP (1.00) | SULT1A1APPGLAGAAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180028694-A1 | THIOFLAVIN DERIVATIVES FOR USE IN ANTEMORTEM DIAGNOSIS OF ALZHEIMER'S DISEASE AND IN VIVO IMAGING AND PREVENTION OF AMYLOID DEPOSITION | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2018-02-01 | — | — | US | disclosed |
| US-9808541-B2 | Thioflavin derivatives for use in antemortem diagnosis of Alzheimer's disease and in vivo imaging and prevention of amyloid deposition | University of Pittsburgh—Of the Commonwealth System of Higher Eduation (US) | 2017-11-07 | — | — | US | disclosed |
| US-20150165073-A1 | THIOFLAVIN DERIVATIVES FOR USE IN ANTEMORTEM DIAGNOSIS OF ALZHEIMER'S DISEASE AND IN VIVO IMAGING AND PREVENTION OF AMYLOID DEPOSITION | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2015-06-18 | — | — | US | disclosed |
| US-8911707-B2 | Thioflavin derivatives for use in antemortem diagnosis of alzheimer's disease and in vivo imaging and prevention of amyloid deposition | University of Pittsburgh—of the Commonwealth System of Higher Education (US) | 2014-12-16 | — | — | US | disclosed |
| US-8580229-B2 | Amyloid imaging as a surrogate marker for efficacy of anti-amyloid therapies | University of Pittsburgh—of the Commonwealth System of Higher Education (US) | 2013-11-12 | — | — | US | disclosed |
| US-20130236394-A1 | THIOFLAVIN DERIVATIVES FOR USE IN ANTEMORTEM DIAGNOSIS OF ALZHEIMER`S DISEASE AND IN VIVO IMAGING AND PREVENTION OF AMYLOID DEPOSITION | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2013-09-12 | — | — | US | disclosed |
| EP-1771208-B1 | USE OF THIOFLAVIN RADIOLABELED DERIVATIVES IN AMYLOID IMAGING FOR ASSESSING ANTI-AMYLOID THERAPIES | UNIV PITTSBURGH (US) | 2013-06-19 | — | — | EP | disclosed |
| US-8404213-B2 | Thioflavin derivatives for use in antemortem diagnosis of Alzheimer's disease and in vivo imaging and prevention of amyloid deposition | University of Pittsburgh—of the Commonwealth System of Higher Education (US) | 2013-03-26 | — | — | US | disclosed |
| US-20130045164-A1 | AMYLOID IMAGING AS A SURROGATE MARKER FOR EFFICACY OF ANTI-AMYLOID THERAPIES | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2013-02-21 | — | — | US | disclosed |
| US-8343457-B2 | Amyloid imaging as a surrogate marker for efficacy of anti-amyloid therapies | University of Pittsburgh—of the Commonwealth System of Higher Education (US) | 2013-01-01 | — | — | US | disclosed |
| US-20080286202-A1 | Method of Diagnosing Prodromal Forms of Diseases Associated With Amyloid Deposition | UNIVERSITY OF PITTSBURGH (US) | 2008-11-20 | — | — | US | disclosed |
| US-20080219931-A1 | Amyloid Imaging as a Surrogate Marker for Efficacy of Anti-Amyloid Therapies | UNIVERSITY OF PITTSBURGH | 2008-09-11 | — | — | US | disclosed |
| US-20080219931-A1 | Amyloid Imaging as a Surrogate Marker for Efficacy of Anti-Amyloid Therapies | UNIVERSITY OF PITTSBURGH | 2008-09-11 | — | — | US | disclosed |
| US-7384966-B2 | 2-arylbenzothiazole derivatives | PHARMINXO LIMITED (GB) | 2008-06-10 | — | — | US | disclosed |
| US-20080021077-A1 | Bioavailability, nontoxic; 2-(3'-Iodo-4'-aminophenyl)-6-methoxybenzothiazole | UNIVERSITY OF PITTSBURGH | 2008-01-24 | — | — | US | disclosed |
| US-20080021077-A1 | Bioavailability, nontoxic; 2-(3'-Iodo-4'-aminophenyl)-6-methoxybenzothiazole | UNIVERSITY OF PITTSBURGH | 2008-01-24 | — | — | US | disclosed |
| US-7270800-B2 | Imaging amyloid deposits in living patients, with an amyloid binding agents having radiolabeled iodine; radiotherapy | UNIVERSITY OF PITTSBURGH (US) | 2007-09-18 | — | — | US | disclosed |
| US-7270800-B2 | Imaging amyloid deposits in living patients, with an amyloid binding agents having radiolabeled iodine; radiotherapy | UNIVERSITY OF PITTSBURGH (US) | 2007-09-18 | — | — | US | disclosed |
| WO-2007035405-A2 | IN-VIVO AND IN-VITRO METHOD FOR DETECTING AMYLOID DEPOSITS HAVING AT LEAST ONE AMYLOIDOGENIC PROTEIN | UNIVERSITY OF PITTSBURGH (US) | 2007-03-29 | — | — | WO | disclosed |
| US-20060063816-A1 | 2-Arylbenzothiazole derivatives | STEVENS MALCOLM F G | 2006-03-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130236394-A1 | THIOFLAVIN DERIVATIVES FOR USE IN ANTEMORTEM DIAGNOSIS OF ALZHEIMER`S DISEASE AND IN VIVO IMAGING AND PREVENTION OF AMYLOID DEPOSITION | APP, PSEN2, MAPT | SULT1A1 673/4885APP 1/4885GLA 188/4885 |
| US-20130045164-A1 | AMYLOID IMAGING AS A SURROGATE MARKER FOR EFFICACY OF ANTI-AMYLOID THERAPIES | TTR, APP, SAAL1 | SULT1A1 2536/4885APP 2/4885GLA 48/4885 |
| US-20180028694-A1 | THIOFLAVIN DERIVATIVES FOR USE IN ANTEMORTEM DIAGNOSIS OF ALZHEIMER'S DISEASE AND IN VIVO IMAGING AND PREVENTION OF AMYLOID DEPOSITION | APP, PSEN2, MAPT | SULT1A1 642/4885APP 1/4885GLA 180/4885 |
| US-20150165073-A1 | THIOFLAVIN DERIVATIVES FOR USE IN ANTEMORTEM DIAGNOSIS OF ALZHEIMER'S DISEASE AND IN VIVO IMAGING AND PREVENTION OF AMYLOID DEPOSITION | APP, PSEN2, MAPT | SULT1A1 642/4885APP 1/4885GLA 180/4885 |
| US-20080021077-A1 | Bioavailability, nontoxic; 2-(3'-Iodo-4'-aminophenyl)-6-methoxybenzothiazole | APOL1, APOB, APP | SULT1A1 639/4885APP 3/4885GLA 806/4885 |
| US-20060063816-A1 | 2-Arylbenzothiazole derivatives | CX3CR1, HCN2, CYBB | SULT1A1 285/4885APP 1876/4885GLA 1900/4885 |
| US-20080219931-A1 | Amyloid Imaging as a Surrogate Marker for Efficacy of Anti-Amyloid Therapies | TTR, APP, SAAL1 | SULT1A1 2536/4885APP 2/4885GLA 48/4885 |
| US-20080286202-A1 | Method of Diagnosing Prodromal Forms of Diseases Associated With Amyloid Deposition | PSEN2, PSEN1, APP | SULT1A1 4158/4885APP 3/4885GLA 57/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.